Alliance Pharma FY profits seen in line with expectations.
International healthcare firm Alliance Pharma said on Friday that FY24 group profits would be in line with expectations despite a modest downturn in revenues.
Alliance Pharma
31 January 2025 09:32:40
Source: Sharecast
Alliance Pharma said it had delivered group see-through revenues of £180.3m in FY24, down 1% year-on-year, but noted that while revenues declined in some of its brands, it had delivered a "strong performance" in Kelo-Cote, MacuShield, Hydromol and Forceval.
Chief executive Nick Sedgwick said: " I am pleased that performance in 2024 is in-line with expectations. Whilst we have much to do as we work on our transformation plans, I am confident that our strong portfolio of clinically differentiated brands will deliver predictable organic revenue growth over the mid-long term."
As of 0930 GMT, Alliance Pharma shares were up 0.33% at 61.40p.
Reporting by Iain Gilbert at Sharecast.com
N/A
ISIN:
N/A
Exchange: N/A
Sell:
N/A
Buy:
N/A
Change:
Date:
Prices delayed by at least 15 minutes
Compare our accounts
If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.
Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.
